Multiparametric Evaluation of One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia After Intensive Care Unit

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Many of the patients hospitalized for a severe form of SARSCoV-2 respiratory impairment require prolonged intensive care that can be complicated in the short term, In the medium and long term, physical and psychological sequelae can affect patients' quality of life and prevent a return to normal working life. To date, there is little data on the fate of patients treated in Resuscitation for a severe form of COVID-19, both in terms of respiratory sequelae, as well as in terms of psychological sequelae and their quality of life. The objective of this study is to be able to describe and evaluate the possible physical and psychological sequelae and quality of life of patients hospitalized in Resuscitation for a severe form of COVID-19 in the short (3 and 6 months), medium (1 year) and long (5 years) End of their stay in ICU. To do this, we want to carry out a prospective, observational and monocentric study in the consultation department of the Nice CHU. All patients admitted to Resuscitation for a severe form of COVID-19 who have accepted the longitudinal medical follow-up proposed by the Nice CHU will be included in the study and data from the computerized medical record will be analyzed.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Patients hospitalized in ICU for an ARDS table

• PCR SARSCoV-2 nasopharyngeal or positive pulmonary samples

Locations
Other Locations
France
CHU de Nice
RECRUITING
Nice
Contact Information
Primary
Clément SACCHERI
saccheri.c@chu-nice.fr
0033492035510
Backup
Jean DELLAMONICA, MD, PhD
dellamonica.j@chu-nice.fr
0033492035510
Time Frame
Start Date: 2020-06-16
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 150
Treatments
Survivors of Intensive care unit patients
Survivors of severe COVID-19 pneumonia after intensive care unit
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Nice

This content was sourced from clinicaltrials.gov